Pharming Group N.V. PHAR
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.84% | 15.21% | 26.56% | 26.78% | 22.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.84% | 15.21% | 26.56% | 26.78% | 22.44% |
| Cost of Revenue | 35.97% | 24.01% | 28.53% | 20.71% | 14.31% |
| Gross Profit | 4.47% | 14.12% | 26.29% | 27.50% | 23.49% |
| SG&A Expenses | -8.21% | -2.70% | 9.73% | 1.60% | 6.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 29.57% | -19.41% | -21.77% | -113.08% | -116.43% |
| Total Operating Expenses | 6.54% | 6.21% | 14.16% | 1.41% | 3.16% |
| Operating Income | 29.06% | 514.89% | 1,011.41% | 235.40% | 159.86% |
| Income Before Tax | 354.87% | 643.82% | 251.30% | 185.61% | 122.61% |
| Income Tax Expenses | -45.47% | -27.82% | 207.85% | 2,256.43% | 675.90% |
| Earnings from Continuing Operations | 209.26% | 185.52% | 121.43% | 100.39% | 36.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -14.79% | -- | -- | -- |
| Net Income | 213.43% | 187.56% | 124.08% | 102.14% | 38.46% |
| EBIT | 29.06% | 514.89% | 1,011.41% | 235.40% | 159.86% |
| EBITDA | 4.53% | 108.43% | 167.36% | 633.17% | 345.83% |
| EPS Basic | 239.10% | 204.11% | 141.27% | 113.50% | 34.80% |
| Normalized Basic EPS | -93.10% | 520.00% | -126.53% | 133.92% | 133.92% |
| EPS Diluted | 223.78% | 196.04% | 134.52% | 111.15% | 29.90% |
| Normalized Diluted EPS | -96.55% | 500.00% | -128.57% | 133.92% | 133.92% |
| Average Basic Shares Outstanding | -1.41% | -0.73% | -3.11% | 2.43% | -3.67% |
| Average Diluted Shares Outstanding | 2.21% | 2.89% | 0.53% | 2.43% | -3.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |